Hold control (command on a Mac) and press the + key as many times as necessary to increase the font size.
Hold control (command on a Mac) and press the - key to reduce the font size. - hide
Online Bulletin Board Support Group Users: click "Forum" to view archives and post messages. - hide
Show/Hide

***San Diego Patient Event Postponed***

March 10, 2020

After reviewing new guidelines from UCSD regarding COVID-19, we have made the decision to postpone our Graves'/TED seminar, which was previously scheduled for 4/11. 

The UCSD guidelines, which are effective through May 10th, "strongly recommend" cancellation or postponement of events that bring groups of more than 15 people to campus. You can read the UCSD guidance in full here:

https://ucsdnews.ucsd.edu/covid-19?_ga=2.17876537.1425187151.1583822344-232675264.1583822344

Our intention is to reschedule this event as soon as it is deemed safe to do so.

Read More

  • ***San Diego Patient Event Postponed***

    March 10, 2020

    After reviewing new guidelines from UCSD regarding COVID-19, we have made the decision to postpone our Graves'/TED seminar, which was previously scheduled for 4/11. 

    The UCSD guidelines, which are effective through May 10th, "strongly recommend" cancellation or postponement of events that bring groups of more than 15 people to campus. You can read the UCSD guidance in full here:

    https://ucsdnews.ucsd.edu/covid-19?_ga=2.17876537.1425187151.1583822344-232675264.1583822344

    Our intention is to reschedule this event as soon as it is deemed safe to do so.

    Read More

  • Tepezza FDA Approval (teprotumumab-trbw)

    Jan. 21, 2020

    BREAKING NEWS: The FDA has approved Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease. Wiley Chambers, M.D., deputy director of the Division of Transplant and Ophthalmology Products in the FDA’s Center for Drug Evaluation and Research noted, “Today’s approval marks an important milestone for the treatment of thyroid eye disease. Currently, there are very limited treatment options for this potentially debilitating disease. This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non surgical treatment option.” Read more from the FDA regarding research results, adverse reactions, and the FDA's review process.

    Read More

  • Neuropsychiatric Symptoms and Graves'

    July 2, 2019

    If you enjoyed the GDATF's patient bulletin "What's Wrong With Me? I'm Not Myself Anymore", then you won't want to miss the sequel! "A survey study of neuropsychiatric complaints in patients with Graves’ disease: A reassessment of self-reported symptoms and current practice 20 years later" is now available as an e-manuscript that is free with Kindle Unlimited or $2.99 with Amazon. Many thanks to Dr. James Arruda for conducting this ...

    Read More

  • Recent News

  • Recent Forum Posts

Questions? Problems? Please contact us at [email protected] or 877-643-3123.

GDATF on Facebook
Thank you to our Diamond Sponsors:
Quidel-Thyretain The Bell Charitable Foundation

Support the GDATF and become a member today!

© 2020 Graves' Disease & Thyroid Foundation